Abstract
Purpose
To identify the characteristics and outcome of panuveitis of undetermined origin (PUO) after diagnostic vitrectomy.
Methods
Retrospective analysis of all patients who underwent vitrectomy for diagnostic/therapeutic purposes from 2013 to 2020, whose vitreous biopsies turned out negative and final diagnoses were not clinically supported.
Results
Of 122 operated eyes, 36 eyes (29.5%) were defined as PUO (67.8 ± 14.9 years). The presenting clinical picture revealed a predominantly bilateral condition (70% of eyes) with significant posterior segment involvement: 3.1 ± 0.6 vitritis, 61.1% of eyes with retinal vasculitis, 44.4% with macular edema, and 30.6% with exudative retinal detachment. Presenting visual acuity was 1.2 ± 0.7 logMAR, and up to 90% remained stable or improved vision over a ~ 3.5 year observation period. None of the presenting clinical features turned out to be predictive of final visual outcome or survival.
Conclusions
PUO is present in up to 30% of cases after diagnostic/therapeutic vitrectomy. This mainly bilateral condition shows chronic and overall stable long-term outcome, generally with retained steady visual function.
Similar content being viewed by others
Data and material availability
The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.
References
Uy HS, Foster CS (1999) Diagnostic vitrectomy and uveitis. Int Ophthalmol Clin 39:223–235
Margolis R (2008) Diagnostic vitrectomy for the diagnosis and management of posterior uveitis of unknown etiology. Curr Opin Ophthalmol 19:218–224
Manku H, McCluskey P (2005) Diagnostic vitreous biopsy in patients with uveitis: a useful investigation? Clin Exp Ophthalmol 33:604–610
Garweg JG, Wanner D, Sarra GM, Altwegg M, Loosli H, Kodjikian L, Halberstadt M (2006) The diagnostic yield of vitrectomy specimen analysis in chronic idiopathic endogenous uveitis. Eur J Ophthalmol 16:588–594
Margolis R, Brasil OFM, Lowder CY, Singh RP, Kaiser PK, Smith SD, Perez VL, Sonnie C, Sears JE (2007) Vitrectomy for the diagnosis and management of uveitis of unknown cause. Ophthalmology 114:1893–1897
Zhao XY, Xia S, Chen YX (2020) Role of diagnostic pars plana vitrectomy in determining the etiology of uveitis initially unknown. Retina 40:359–369
Sugita S, Ogawa M, Shimizu N et al (2013) Use of a comprehensive polymerase chain reaction system for diagnosis of ocular infectious diseases. Ophthalmology 120:1761–1768
Oahalou A, Schellekens PAWJF, De Groot-Mijnes JD, Rothova A (2014) Diagnostic pars plana vitrectomy and aqueous analyses in patients with uveitis of unknown cause. Retina 34:108–114
Svozilkova P, Heissigerova J, Brichova M, Kalvodova B, Dvorak J, Rihova E (2011) The role of pars plana vitrectomy in the diagnosis and treatment of uveitis. Eur J Ophthalmol 21:89–97
Miserocchi E, Ferreri AJM, Giuffrè C, Cangi MG, Francaviglia I, Calimeri T, Ponzoni M, Pecciarini L, Bandello FM, Modorati GM (2019) MYD88 L265P mutation detection in the aqueous humor of patients with vitreoretinal lymphoma. Retina 39:679–684
Jabs DA, Nussenblatt RB, Rosenbaum JT et al (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140:509–516
Codenotti M, Iuliano L, Bandello F (2011) Elegant solution for nonsterile tube handling in “vitreous trap” preparation. Retina. https://doi.org/10.1097/IAE.0B013E318234CB1C
Moshfeghi AA, Albini TA, Kitchens JW, Leng T, Moshfeghi DM (2011) To the Editor. Retina 31:426–427
Acknowledgements
Not applicable.
Funding
No funding was received for this research.
Author information
Authors and Affiliations
Contributions
LI: research design, data acquisition and analysis, interpretation of data, drafting and critical revision of the manuscript, final approval of the version to be published. MK, EC, EM, GM: data acquisition and analysis, critical revision of the manuscript and final approval of the version to be published. FB, MC: interpretation of data, critical revision of the manuscript and final approval of the version to be published.
Corresponding author
Ethics declarations
Conflict of interest
Lorenzo Iuliano, Mirko Kacerik, Eleonora Corbelli, Elisabetta Miserocchi, Giulio Modorati, Marco Codenotti have not disclosed any competing interests. Francesco Bandello is a consultant for: Alcon (Fort Worth,Texas, USA), Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc (Irvine, California, USA), Farmila-Thea (Clermont-Ferrand, France), Bayer Shering-Pharma (Berlin, Germany), Bausch And Lomb (Rochester, New York, USA), Genentech (San Francisco, California, USA), Hoffmann-La-Roche (Basel, Switzerland), Novagali Pharma (Évry, France), Novartis (Basel, Switzerland), Sanofi-Aventis (Paris, France), Thrombogenics (Heverlee,Belgium), Zeiss (Dublin, USA).
Ethics approval
All procedures performed involving human participants were in accordance with the ethical standards of the Institutional Review Board of the San Raffaele Scientific Institute and with the 1964 Helsinki Declaration and its later amendments. All patients signed a general informed consent form, which was specifically designed and approved by the Institutional Review Board of the San Raffaele Scientific Institute solely for participants of observational retrospective studies.
Consent for publication
The authors concur on submission and eventual publication.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Iuliano, L., Kacerik, M., Corbelli, E. et al. Panuveitis of undetermined origin after diagnostic pars plana vitrectomy: clinical characterization and long-term outcome from a tertiary referral center. Int Ophthalmol 43, 2841–2849 (2023). https://doi.org/10.1007/s10792-023-02683-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10792-023-02683-5